Kyriakoulis Konstantinos G, Trontzas Ioannis P, Kyriakoulis Ioannis G, Terentes-Printzios Dimitrios, Papageorgiou Nikolaos-Georgios, Fyta Eleni, Kotteas Elias, Kollias Anastasios
Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, 11527 Athens, Greece.
1st Department of Cardiology, Athens Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.
Rev Cardiovasc Med. 2023 Feb 6;24(2):54. doi: 10.31083/j.rcm2402054. eCollection 2023 Feb.
Coronavirus disease 2019 (COVID-19) had a major impact on healthcare systems worldwide. During the early phase of the pandemic many elective procedures were postponed. At the same time, the safe and effective management of medical emergencies such as ST-segment elevation myocardial infarction (STEMI) has been a challenge.
A systematic literature search was conducted aiming to identify published guidance reports by national or international societies regarding the management of patients suffering STEMI in the era of COVID-19.
Among 1681 articles initially retrieved, six fulfilled the inclusion criteria and were included in the systematic review. Two reports were international consensus documents, while four reports were national guidance statements from Asian countries (Taiwan, India, Iran, and China). Most documents were drafted during the early phase of the pandemic. According to the international consensus documents, percutaneous coronary intervention (PCI) should be regarded as the reperfusion method of choice. On the other hand, in three out of four national consensus statements (Taiwan, Iran and China) fibrinolysis was considered as the reperfusion method of choice for STEMI in suspected/confirmed patients with COVID-19, unless contraindicated or in the presence of high cardiovascular risk clinical features. Authors of all documents underlined the need for early COVID-19 testing in patients with STEMI to better determine the next therapeutical steps.
National and international consensus statements for STEMI management in the era of COVID-19 have been published mainly during the early peak phase of the pandemic. Authors recognise that these recommendations are mainly based on expert opinions and observational data. As global immunization rates increase and methods for rapid COVID-19 detection are widely available, the implementation of traditional evidence-based practices used before the pandemic is becoming more feasible.
2019冠状病毒病(COVID-19)对全球医疗系统产生了重大影响。在疫情早期阶段,许多择期手术被推迟。与此同时,对ST段抬高型心肌梗死(STEMI)等医疗紧急情况进行安全有效的管理一直是一项挑战。
进行了一项系统的文献检索,旨在确定国家或国际协会发布的关于COVID-19时代STEMI患者管理的指导报告。
在最初检索的1681篇文章中,有6篇符合纳入标准并被纳入系统评价。两篇报告是国际共识文件,而四篇报告是亚洲国家(台湾、印度、伊朗和中国)的国家指导声明。大多数文件是在疫情早期阶段起草的。根据国际共识文件,经皮冠状动脉介入治疗(PCI)应被视为首选的再灌注方法。另一方面,在四份国家共识声明中的三份(台湾、伊朗和中国)中,对于疑似/确诊COVID-19的STEMI患者,除非有禁忌证或存在高心血管风险临床特征,纤维蛋白溶解被视为首选的再灌注方法。所有文件的作者都强调,对STEMI患者进行早期COVID-19检测对于更好地确定下一步治疗步骤的必要性。
COVID-19时代STEMI管理的国家和国际共识声明主要在疫情早期高峰阶段发布。作者认识到这些建议主要基于专家意见和观察数据。随着全球免疫接种率的提高以及快速检测COVID-19的方法广泛可用,疫情前使用的传统循证实践的实施变得更加可行。